{
    "clinical_study": {
        "@rank": "38356", 
        "acronym": "Hyper2S", 
        "arm_group": [
            {
                "arm_group_label": "normoxia and isotonic saline", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Administration of oxygen in order to maintain SaO2 between 88% and 95%. Fluid resuscitation if needed with isotonic saline during 3 days."
            }, 
            {
                "arm_group_label": "normoxia and 3% hypertonic saline", 
                "arm_group_type": "Active Comparator", 
                "description": "Administration of oxygen in order to maintain SaO2 between 88% and 95%. Fluid resuscitation if needed with 3% hypertonic saline during 3 days."
            }, 
            {
                "arm_group_label": "hyperoxia and isotonic saline", 
                "arm_group_type": "Active Comparator", 
                "description": "Administration of oxygen with FiO2 = 100% during the first 24 hours and after switch oxygen administration to usual care.\nFluid resuscitation if needed with isotonic saline during 3 days."
            }, 
            {
                "arm_group_label": "hyperoxia and 3% hypertonic saline", 
                "arm_group_type": "Active Comparator", 
                "description": "Administration of oxygen with FiO2 = 100% during the first 24 hours and after switch oxygen administration to usual care.\nFluid resuscitation if needed with 3% hypertonic saline during 3 days."
            }
        ], 
        "brief_summary": {
            "textblock": "Assessment of the effect of hyperoxia and hypertonic saline on survival in patients with\n      septic shock Hyperoxia and hypertonic saline may have beneficial effects on organ perfusion\n      and oxygenation and may reduce the organ failure occurences. To date, only scarce data are\n      available. Side effects are not well described. Therefore we designed a randomized clinical\n      trial in order to assess the early administration of hypertonic saline and oxygen in the\n      very early beginning of septic shock."
        }, 
        "brief_title": "Hyperoxia and Hypertonic Saline in Septic Shock", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Septic Shock", 
            "Adult Respiratory Distress Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Respiratory Distress Syndrome, Newborn", 
                "Respiratory Distress Syndrome, Adult", 
                "Acute Lung Injury", 
                "Shock", 
                "Shock, Septic"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study is designed as factorial 2x2. Patients will be stratified at the randomisation\n      according the presence or absence of Acute Respiratory Distress Syndrome in order to perform\n      a sub group analysis for all outcome criteria."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients with less than 6 hours septic shock according criteria of Bone\n\n          -  minimal dose of catecholamines at least 0.1 \u00b5g/Kg/min\n\n          -  patient with mechanical ventilation\n\n          -  written informed consent\n\n        Exclusion Criteria:\n\n          -  age < 18 years\n\n          -  pregnancy\n\n          -  participation in other trial with the same endpoint\n\n          -  moribund\n\n          -  absence of registration in french health care system\n\n          -  patient protected by law\n\n          -  hypernatremia < 130 mmol/l ou > 145 mmol/l\n\n          -  patient with P/F < 100 mm Hg with PEEP > 5 cms of water\n\n          -  intracranial hypertension\n\n          -  patient admitted for cardiac arrest\n\n          -  overt cardiac failure"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "800", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01722422", 
            "org_study_id": "PHRC 11-05"
        }, 
        "intervention": {
            "arm_group_label": [
                "normoxia and isotonic saline", 
                "normoxia and 3% hypertonic saline", 
                "hyperoxia and isotonic saline", 
                "hyperoxia and 3% hypertonic saline"
            ], 
            "intervention_name": "oxygen and  saline", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "sepsis", 
            "shock", 
            "hyperoxia", 
            "hypertonic saline"
        ], 
        "lastchanged_date": "November 2, 2012", 
        "location": {
            "contact": {
                "email": "piasfar@chu-angers.fr", 
                "last_name": "ASFAR Pierre, Pr MD PhD", 
                "phone": "33-(0)2-41-35-38-15"
            }, 
            "facility": {
                "address": {
                    "city": "Angers", 
                    "country": "France", 
                    "zip": "49933"
                }, 
                "name": "University Hospital Angers"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "4", 
        "overall_contact": {
            "email": "piasfar@chu-angers.fr", 
            "last_name": "ASFAR Pierre, Pr MD phD", 
            "phone": "+33-2-41-35-38-15"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "French: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "all-cause mortality", 
            "safety_issue": "Yes", 
            "time_frame": "day 28"
        }, 
        "reference": [
            {
                "PMID": "21164398", 
                "citation": "Calzia E, Asfar P, Hauser B, Matejovic M, Ballestra C, Radermacher P, Georgieff M. Hyperoxia may be beneficial. Crit Care Med. 2010 Oct;38(10 Suppl):S559-68. doi: 10.1097/CCM.0b013e3181f1fe70."
            }, 
            {
                "PMID": "7540812", 
                "citation": "Goertz AW, Mehl T, Lindner KH, Rockemann MG, Schirmer U, Schwilk B, Georgieff M. Effect of 7.2% hypertonic saline/6% hetastarch on left ventricular contractility in anesthetized humans. Anesthesiology. 1995 Jun;82(6):1389-95."
            }, 
            {
                "PMID": "12415443", 
                "citation": "Oliveira RP, Weingartner R, Ribas EO, Moraes RS, Friedman G. Acute haemodynamic effects of a hypertonic saline/dextran solution in stable patients with severe sepsis. Intensive Care Med. 2002 Nov;28(11):1574-81. Epub 2002 Oct 1."
            }, 
            {
                "PMID": "9637711", 
                "citation": "Junger WG, Hoyt DB, Davis RE, Herdon-Remelius C, Namiki S, Junger H, Loomis W, Altman A. Hypertonicity regulates the function of human neutrophils by modulating chemoattractant receptor signaling and activating mitogen-activated protein kinase p38. J Clin Invest. 1998 Jun 15;101(12):2768-79."
            }, 
            {
                "PMID": "9137245", 
                "citation": "Coimbra R, Hoyt DB, Junger WG, Angle N, Wolf P, Loomis W, Evers MF. Hypertonic saline resuscitation decreases susceptibility to sepsis after hemorrhagic shock. J Trauma. 1997 Apr;42(4):602-6; discussion 606-7."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01722422"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "all-cause mortality", 
                "safety_issue": "Yes", 
                "time_frame": "day 90"
            }, 
            {
                "measure": "evolution of organ failures", 
                "safety_issue": "Yes", 
                "time_frame": "day 1 to day 28"
            }, 
            {
                "measure": "catecholamines free days", 
                "safety_issue": "No", 
                "time_frame": "day 1 to day 28"
            }, 
            {
                "measure": "mechanical ventilation free days", 
                "safety_issue": "Yes", 
                "time_frame": "day 1 to day 28"
            }, 
            {
                "measure": "safety data", 
                "safety_issue": "Yes", 
                "time_frame": "day 1 to day 90"
            }
        ], 
        "source": "University Hospital, Angers", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Angers", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}